Literature DB >> 34065983

Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.

Maxime Blijlevens1, Jing Li1, Victor W van Beusechem1.   

Abstract

Dysregulation of messenger RNA (mRNA) processing-in particular mRNA splicing-is a hallmark of cancer. Compared to normal cells, cancer cells frequently present aberrant mRNA splicing, which promotes cancer progression and treatment resistance. This hallmark provides opportunities for developing new targeted cancer treatments. Splicing of precursor mRNA into mature mRNA is executed by a dynamic complex of proteins and small RNAs called the spliceosome. Spliceosomes are part of the supraspliceosome, a macromolecular structure where all co-transcriptional mRNA processing activities in the cell nucleus are coordinated. Here we review the biology of the mRNA splicing machinery in the context of other mRNA processing activities in the supraspliceosome and present current knowledge of its dysregulation in lung cancer. In addition, we review investigations to discover therapeutic targets in the spliceosome and give an overview of inhibitors and modulators of the mRNA splicing process identified so far. Together, this provides insight into the value of targeting the spliceosome as a possible new treatment for lung cancer.

Entities:  

Keywords:  NSCLC; alternative splicing; splicing dysregulation; splicing factors

Year:  2021        PMID： 34065983      PMCID： PMC8150589          DOI： 10.3390/ijms22105110

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN： 1422-0067            Impact factor:   5.923


  396 in total

1.  Native spliceosomes assemble with pre-mRNA to form supraspliceosomes.

Authors:  Maia Azubel; Naomi Habib; Ruth Sperling; Joseph Sperling
Journal:  J Mol Biol       Date:  2005-12-12       Impact factor: 5.469

2.  Functional splicing network reveals extensive regulatory potential of the core spliceosomal machinery.

Authors:  Panagiotis Papasaikas; J Ramón Tejedor; Luisa Vigevani; Juan Valcárcel
Journal:  Mol Cell       Date:  2014-12-04       Impact factor: 17.970

3.  Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Authors:  Jia Yi Fong; Luca Pignata; Pierre-Alexis Goy; Kimihito Cojin Kawabata; Stanley Chun-Wei Lee; Cheryl M Koh; Daniele Musiani; Enrico Massignani; Andriana G Kotini; Alex Penson; Cheng Mun Wun; Yudao Shen; Megan Schwarz; Diana Hp Low; Alexander Rialdi; Michelle Ki; Heike Wollmann; Slim Mzoughi; Florence Gay; Christine Thompson; Timothy Hart; Olena Barbash; Genna M Luciani; Magdalena M Szewczyk; Bas J Wouters; Ruud Delwel; Eirini P Papapetrou; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Mark D Minden; Jian Jin; Ari Melnick; Tiziana Bonaldi; Omar Abdel-Wahab; Ernesto Guccione
Journal:  Cancer Cell       Date:  2019-08-12       Impact factor: 31.743

4.  Interaction between the RNA binding domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein determines early spliceosome assembly.

Authors:  Suhyung Cho; Amy Hoang; Rahul Sinha; Xiang-Yang Zhong; Xiang-Dong Fu; Adrian R Krainer; Gourisankar Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

5.  Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I.

Authors:  F Rossi; E Labourier; T Forné; G Divita; J Derancourt; J F Riou; E Antoine; G Cathala; C Brunel; J Tazi
Journal:  Nature       Date:  1996-05-02       Impact factor: 49.962

6.  RNA editing in nascent RNA affects pre-mRNA splicing.

Authors:  Yun-Hua Esther Hsiao; Jae Hoon Bahn; Yun Yang; Xianzhi Lin; Stephen Tran; Ei-Wen Yang; Giovanni Quinones-Valdez; Xinshu Xiao
Journal:  Genome Res       Date:  2018-05-03       Impact factor: 9.043

7.  PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells.

Authors:  Athena Georgilis; Sabrina Klotz; Christopher J Hanley; Nicolas Herranz; Benedikt Weirich; Beatriz Morancho; Ana Carolina Leote; Luana D'Artista; Suchira Gallage; Marco Seehawer; Thomas Carroll; Gopuraja Dharmalingam; Keng Boon Wee; Marco Mellone; Joaquim Pombo; Danijela Heide; Ernesto Guccione; Joaquín Arribas; Nuno L Barbosa-Morais; Mathias Heikenwalder; Gareth J Thomas; Lars Zender; Jesús Gil
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

Review 8.  Pick one, but be quick: 5' splice sites and the problems of too many choices.

Authors:  Xavier Roca; Adrian R Krainer; Ian C Eperon
Journal:  Genes Dev       Date:  2013-01-15       Impact factor: 11.361

Review 9.  m6 A RNA methylation: from mechanisms to therapeutic potential.

Authors:  P Cody He; Chuan He
Journal:  EMBO J       Date:  2021-01-20       Impact factor: 11.598

10.  Interplay between pre-mRNA splicing and microRNA biogenesis within the supraspliceosome.

Authors:  Lily Agranat-Tamir; Noam Shomron; Joseph Sperling; Ruth Sperling
Journal:  Nucleic Acids Res       Date:  2014-01-24       Impact factor: 16.971
View more
  5 in total

1.  Identification of uPAR Variants Acting as ceRNAs in Leukaemia Cells.

Authors:  Mariaevelina Alfieri; Anna Li Santi; Luigia Meo; Valentina Giudice; Carmine Selleri; Pia Ragno
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

2.  Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes.

Authors:  Deeksha Malhan; Alireza Basti; Angela Relógio
Journal:  NPJ Syst Biol Appl       Date:  2022-05-12

Review 3.  Alternative RNA splicing in cancer: what about adult T-cell leukemia?

Authors:  Julie Tram; Jean-Michel Mesnard; Jean-Marie Peloponese
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

4.  A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer.

Authors:  Jamal Elhasnaoui; Giulio Ferrero; Valentina Miano; Lorenzo Franchitti; Isabella Tarulli; Lucia Coscujuela Tarrero; Santina Cutrupi; Michele De Bortoli
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

5.  Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma.

Authors:  Zhili Zeng; Xiao Jiang; Zhibin Pan; Ruisheng Zhou; Zhuangteng Lin; Ying Tang; Ying Cui; Enxin Zhang; Zebiao Cao
Journal:  Aging (Albany NY)       Date:  2021-10-04       Impact factor: 5.682
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.